INS and type 2 diabetes mellitus: Butyrate, a specific SCFA, reduces energy expenditure by increasing plasma levels of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and PYY, all of which have key implications in managing T2D due to their effects on glucose metabolism, insulin sensitivity, and appetite regulation [74].